Tempus AI Option Alert: Jun 18 $90 Calls Sweep (32) near the Bid: 495 vs 978 OI; Earnings 11/3 After Close [est] 

Tempus AI Option Alert: Jun 18 $90 Calls Sweep (32) near the Bid: 495 @ $16.407 vs 978 OI; Earnings 11/3 After Close [est] Ref=$79.695

Tempus AI

TEMPUS AI INC

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.

Los,Angeles,,California,-,July,6,2025:,Ark,Invest,Logo

Equities

News

Markets

ETFs

ARKK

Una vendita significativa sul titolo biotech scuote gli analisti: quali sono le implicazioni per gli investitori?

Cathie Wood (Ark Invest): ecco la mossa a sorpresa su Tempus AI

Russia,Moscow,24.06.2021,Logo,Of,Financial,Investing,Fund,Ark,Invest

$BTC

$ETH

ARKF

ARKG

ARKW

ARKX

COIN

NVDA

Mercoledì Ark Invest, il fondo guidato da Cathie Wood, ha eseguito importanti operazioni di trading su Tempus AI Inc. (NASDAQ:TEM), NVIDIA Corp. (NASDAQ:NVDA), 3iQ Ether Staking 

Gli ultimi movimenti di Ark Invest: Tempus AI, Nvidia, 3iQ Ether Staking ETF e Coinbase

Jim Cramer- AI Is Bigger Than Rate Cuts

Long Ideas

Media

Trading Ideas

INSM

OUST

PAAS

PSNL

TSLA

Un&#39;azione mineraria brilla sul mercato, ma il noto analista frena gli entusiasmi. Non sempre un rialzo è un buon segnale d&#39;acquisto.

Questo titolo sale del 5%, ma per Jim Cramer non è quello giusto

Tempus AI Inc

Tradr 2X Long TEM Daily ETF

J.P. Morgan Exchange-Traded Fund Trust JPMorgan Climate Change Solutions ETF

Touchstone ETF Trust Touchstone Sands Capital Emerging Markets ex-China Growth ETF

TEMCO

PERSOL HLDG CO LTD ORD by Persol Holdings Co Ltd

Persol Holdings Co Ltd

Press Releases

Tempus Announces the Acquisition of Paige

Tempus to Participate in Morgan Stanley's 23rd Annual Global Healthcare Conference

Northwestern Medicine Becomes First Health System to Integrate Tempus' Generative AI Co-Pilot, David, Into Its EHR Platform

Tempus Announces New Study in JCO Precision Oncology Validating PurIST® Algorithm for Enhanced Therapy Selection in Pancreatic Cancer

Tempus Receives U.S. FDA Special 510(k) Clearance for Updated Tempus Pixel Device

Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease

Small Cap

Opinion

Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises

Kuehn Law Encourages Investors of Tempus AI, Inc. to Contact Law Firm

Tempus Receives U.S. FDA 510(k) Clearance for Tempus xR IVD, its RNA NGS In Vitro Diagnostic Device

Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution with Upgraded Tyrer-Cuzick Scoring Approach Incorporating Breast Density

AVAI

BNTX

CRSP

RNLXY

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Tempus AI

Unusual Options Activity for

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO